|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hadjipanayis CG and Van Meir EG: Brain
cancer propagating cells: Biology, genetics and targeted therapies.
Trends Mol Med. 15:519–530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Sakariassen PO, Tsinkalovsky O,
Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen
F, Stuhr L, et al: CD133 negative glioma cells form tumors in nude
rats and give rise to CD133 positive cells. Int J Cancer.
122:761–768. 2008. View Article : Google Scholar
|
|
6
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133+ and CD133− glioblastoma-derived
cancer stem cells show differential growth characteristics and
molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Godlewski J, Newton HB, Chiocca EA and
Lawler SE: MicroRNAs and glioblastoma; the stem cell connection.
Cell Death Differ. 17:221–228. 2010. View Article : Google Scholar
|
|
10
|
Li Y, Guessous F, Zhang Y, Dipierro C,
Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen
TD, et al: MicroRNA-34a inhibits glioblastoma growth by targeting
multiple oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Dutta A and Abounader R: The role
of microRNAs in glioma initiation and progression. Front Biosci.
17:700–712. 2012. View
Article : Google Scholar
|
|
12
|
Guessous F, Zhang Y, Kofman A, Catania A,
Li Y, Schiff D, Purow B and Abounader R: microRNA-34a is tumor
suppressive in brain tumors and glioma stem cells. Cell Cycle.
9:1031–1036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang TQ, Lu XJ, Wu TF, Ding DD, Zhao ZH,
Chen GL, Xie XS, Li B, Wei YX, Guo LC, et al: MicroRNA-16 inhibits
glioma cell growth and invasion through suppression of BCL2 and the
nuclear factor-κB1/MMP9 signaling pathway. Cancer Sci. 105:265–271.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun B, Pu B, Chu D, Chu X, Li W and Wei D:
MicroRNA-650 expression in glioma is associated with prognosis of
patients. J Neurooncol. 115:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bier A, Giladi N, Kronfeld N, Lee HK,
Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S,
et al: MicroRNA-137 is downregulated in glioblastoma and inhibits
the stemness of glioma stem cells by targeting RTVP-1. Oncotarget.
4:665–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y
and Mao Q: MiR-26a enhances the radiosensitivity of glioblastoma
multiforme cells through targeting of ataxia-telangiectasia
mutated. Exp Cell Res. 320:200–208. 2014. View Article : Google Scholar
|
|
17
|
Fan YC, Mei PJ, Chen C, Miao FA, Zhang H
and Li ZL: MiR-29c inhibits glioma cell proliferation, migration,
invasion and angiogenesis. J Neurooncol. 115:179–188. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y,
Chen J, Di G, Chen X and Jiang X: MiR-218 sensitizes glioma cells
to apoptosis and inhibits tumorigenicity by regulating
ECOP-mediated suppression of NF-κB activity. Neuro Oncol.
15:413–422. 2013. View Article : Google Scholar
|
|
19
|
Song L, Huang Q, Chen K, Liu L, Lin C, Dai
T, Yu C, Wu Z and Li J: miR-218 inhibits the invasive ability of
glioma cells by direct downregulation of IKK-β. Biochem Biophys Res
Commun. 402:135–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Yan W, Zhang W, Chen L, You G, Bao
Z, Wang Y, Wang H, Kang C and Jiang T: miR-218 reverses high
invasiveness of glioblastoma cells by targeting the oncogenic
transcription factor LEF1. Oncol Rep. 28:1013–1021. 2012.PubMed/NCBI
|
|
21
|
Rao JS: Molecular mechanisms of glioma
invasiveness: The role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu JT and Kral JG: The NF-kappaB/IkappaB
signaling system: A molecular target in breast cancer therapy. J
Surg Res. 123:158–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Forsyth PA, Wong H, Laing TD, Rewcastle
NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM,
Sutherland G, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and
membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in
different aspects of the pathophysiology of malignant gliomas. Br J
Cancer. 79:1828–1835. 1999. View Article : Google Scholar
|
|
24
|
Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Jin
W and Zhang Y: MicroRNA-218 inhibits glioma invasion, migration,
proliferation, and cancer stem-like cell self-renewal by targeting
the polycomb group gene Bmi1. Cancer Res. 73:6046–6055. 2013.
View Article : Google Scholar
|
|
25
|
Li Y, Wang H, Sun T, Chen J, Guo L, Shen
H, Du Z and Zhou Y: Biological characteristics of a new human
glioma cell line transformed into A2B5+ stem cells. Mol
Cancer. 14:752015. View Article : Google Scholar
|
|
26
|
Lomonaco SL, Finniss S, Xiang C, Lee HK,
Jiang W, Lemke N, Rempel SA, Mikkelsen T and Brodie C: Cilengitide
induces autophagy-mediated cell death in glioma cells. Neuro Oncol.
13:857–865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gey GO, Bang FB and Gey MK: Responses of a
variety of normal and malignant cells to continuous cultivation,
and some practical applications of these responses to problems in
the biology of disease. Ann NY Acad Sci. 58:976–999. 1954.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ogden AT, Waziri AE, Lochhead RA, Fusco D,
Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, et al:
Identification of A2B5+CD133−
tumor-initiating cells in adult human gliomas. Neurosurgery.
62:505–515. 2008. View Article : Google Scholar
|
|
29
|
Tchoghandjian A, Baeza N, Colin C, Cayre
M, Metellus P, Beclin C, Ouafik L and Figarella-Branger D: A2B5
cells from human glioblastoma have cancer stem cell properties.
Brain Pathol. 20:211–221. 2010. View Article : Google Scholar
|
|
30
|
Takeshima T, Johnston JM and Commissiong
JW: Oligodendrocyte-type-2 astrocyte (O-2A) progenitors increase
the survival of rat mesencephalic, dopaminergic neurons from death
induced by serum deprivation. Neurosci Lett. 166:178–182. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Piepmeier JM, Fried I and Makuch R:
Low-grade astrocytomas may arise from different astrocyte lineages.
Neurosurgery. 33:627–632. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bishop M and de la Monte SM: Dual lineage
of astrocytomas. Am J Pathol. 135:517–527. 1989.PubMed/NCBI
|
|
33
|
Zhang B, Sun J, Yu SP, Chen C, Liu B, Liu
ZF, Ren BC, Ming HL and Yang XJ: Rac1+ cells distributed
in accordance with CD 133+ cells in glioblastomas and
the elevated invasiveness of CD 133+ glioma cells with
higher Rac1 activity. Chin Med J. 125:4344–4348. 2012.
|
|
34
|
Huang Q, Zhang QB, Dong J, Wu YY, Shen YT,
Zhao YD, Zhu YD, Diao Y, Wang AD and Lan Q: Glioma stem cells are
more aggressive in recurrent tumors with malignant progression than
in the primary tumor, and both can be maintained long-term in
vitro. BMC Cancer. 8:3042008. View Article : Google Scholar : PubMed/NCBI
|
